{
    "clinical_study": {
        "@rank": "1496", 
        "acronym": "RI-US XL", 
        "arm_group": {
            "arm_group_label": "Resolute Integrity", 
            "arm_group_type": "Other", 
            "description": "Resolute Integrity Stent"
        }, 
        "brief_summary": {
            "textblock": "Prospective, multi-center, non-randomized, single-arm, open-label study to assess the safety\n      and efficacy of the Resolute Integrity Stent for the treatment of de novo lesions in native\n      coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm in patients\n      who receive extended length stents (34 mm or 38 mm) referred to as the Extended Length\n      Study."
        }, 
        "brief_title": "Resolute Integrity US Extended Length Sub-Study(RI-US XL)", 
        "completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this postapproval study is to conduct a prospective, multi-center evaluation\n      of the procedural and clinical outcomes of subjects that are treated with the commercially\n      available 34 mm and 38 mm Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent\n      System.\n\n      Descriptive statistics and 95% confidence intervals will be calculated for clinically\n      relevant variables as described in a separate statistical analysis plan."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "General and Angiographic Inclusion Criteria highlights:\n\n          -  Acceptable candidate for percutaneous coronary intervention (PCI),stenting, and\n             emergency coronary artery bypass graft surgery\n\n          -  Clinical evidence of ischemic heart disease, stable or unstable angina, silent\n             ischemia and/or positive functional study\n\n          -  Informed consent\n\n          -  Patient agrees to comply with specified follow-up evaluations\n\n          -  Single target lesion or two target lesions located in separate coronary arteries\n\n          -  De novo lesion(s) in native coronary artery(ies)\n\n          -  Target lesion(s) \u2264 35 mm in length\n\n          -  Target vessel(s) have reference vessel diameter 2.25 mm to 4.2 mm\n\n        General and Angiographic Exclusion Criteria highlights:\n\n          -  Within 7 days of index procedure platelet count <100,000 cells/mm\u00b3 or >700,000\n             cells/mm\u00b3; White blood cell (WBC) count <3,000 cells/mm\u00b3; serum creatinine level >2.5\n             mg/dl\n\n          -  Acute Myocardial Infarction (MI) within 72 hrs of the intended trial procedure (QWMI\n             or any elevation of CK-MB > lab upper limit of normal)\n\n          -  Previous PCI of target vessel(s) within 9 months prior to the procedure\n\n          -  Planned PCI of any vessel within 30 days post-index procedure and/or planned PCI of\n             target vessel(s) within 12 months post-index procedure\n\n          -  History of stroke or TIA within prior 6 months\n\n          -  Participating in investigational drug/device study that has not completed primary\n             endpoint or interferes with study endpoints\n\n          -  Inability to comply with required trial antiplatelet regimen\n\n          -  Previous stent in target vessel unless it has been at least 9 months since stent\n             placed and target lesion(s) is/are at least 15 mm from previous stent\n\n          -  Target vessel(s) has/have other lesions w/ > 40% diameter stenosis\n\n          -  Unprotected left main coronary artery disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913600", 
            "org_study_id": "IP 126 1C"
        }, 
        "intervention": {
            "arm_group_label": "Resolute Integrity", 
            "description": "Drug eluting stent (DES)", 
            "intervention_name": "Resolute Integrity Stent", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "TARGET LESION REVASCULARIZATION (TLR)", 
            "TARGET VESSEL REVASCULARIZATION (TVR)", 
            "Coronary Artery Disease", 
            "MYOCARDIAL INFARCTION (MI)", 
            "PERCUTANEOUS CORONARY INTERVENTION (PCI)", 
            "STENT THROMBOSIS", 
            "TARGET LESION FAILURE (TLF)"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "last_name": "Ronald Caputo, MD", 
                "phone": "315-234-4412"
            }, 
            "contact_backup": {
                "last_name": "Mary Rolfe, RN", 
                "phone": "315-234-4412"
            }, 
            "facility": {
                "address": {
                    "city": "Syracuse", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "13203"
                }, 
                "name": "St. Joseph's Hospital Health Center"
            }, 
            "investigator": {
                "last_name": "Ronald Caputo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Resolute Integrity US A Postapproval Study of the Medtronic Resolute\u2122 Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composite rate of cardiac death and target vessel myocardial infarction (MI)", 
            "safety_issue": "Yes", 
            "time_frame": "12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Composite endpoints: Major Adverse Cardiac Events (MACE), Target Lesion Failure (TLF), Target Vessel Failure (TVF), Cardiac Death and Target Vessel MI", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinical endpoints: Death, Myocardial Infarction, Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR), Stent Thrombosis, Stroke, Bleeding complications in general", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Dual antiplatelet therapy (DAPT) compliance", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Medtronic Vascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Vascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}